Semaglutide vs Tirzepatide Cost Comparison (2026): Which GLP-1 Saves You More?

Semaglutide list prices run about $1,349 per four-pen Wegovy pack and $969 per Ozempic pen pack, while tirzepatide (Zepbound) lists at $1,060 per pack; none of these brand prices change when you move up in dose. Manufacturer savings cards can drop your cost to as little as $0-$25 per fill if you have eligible commercial insurance, but uninsured cash payers face $11,600-$16,200 a year. Knowing the exact 2026 figures lets you pick the lower-cost GLP-1 or plan another savings strategy.

• The 2026 list price for a four-week Wegovy pack is $1,349.02, regardless of dose (manufacturer site).
• An Ozempic pen pack lists at $969.36 and covers up to 8 weekly 0.5 mg injections when split correctly (manufacturer site).
• Zepbound’s 2026 list price is $1,060.87 per four-dose KwikPen, no matter which strength your doctor prescribes (Eli Lilly).
• Both the Wegovy and Ozempic savings cards can lower eligible commercially insured patients’ copays to as little as $0 for the first fill and $25 thereafter; Zepbound’s card sets a $25 minimum.
• Cash-paying patients spend roughly $4,500 more per year on Wegovy than on Ozempic and $3,400 more than on Zepbound when paying full list price.

Drug companies set one list price, pharmacies add very little

Brand GLP-1 pens have a single “wholesale acquisition cost” (WAC) that applies to every dose strength. Pharmacies usually sell close to that figure because Novo Nordisk and Eli Lilly control distribution tightly. Big-box chains, independents and mail-order pharmacies therefore charge within a few dollars of each other for Wegovy, Ozempic and Zepbound. Markups are rare and steep discounts are even rarer outside of manufacturer programs.

Insurance contracts and patient coupons, not pharmacy shopping, drive most savings. That is why comparing the core WAC numbers first sets realistic expectations before you chase a lower copay.

2026 list price for every weekly dose

Because each pen pack covers four weeks, the monthly cost stays the same as you titrate. The table below lists the official November 2026 WACs.

The numbers above come directly from each manufacturer’s November 1 2026 pricing file. They do not include dispensing fees, taxes or pharmacy price variance, which rarely adds more than $10.

What the savings cards really cover in 2026

Manufacturer coupons only work with commercial insurance. Medicare, Medicaid, TRICARE and cash-pay patients cannot legally use them, and quantity limits apply.

If your plan requires a higher copay than the maximum manufacturer contribution, you pay the difference. A growing number of plans in 2026 use tiered copays that exceed the $150 subsidy, so check your benefits before you assume a $25 cost.

How much will you spend in one year?

The calculator below shows the straight math for 52 weeks of therapy at list price. The totals assume no missed doses, no gaps and no inflation during 2026.

Key takeaway: At list price, Ozempic saves roughly $4,556 over Wegovy and $1,098 over Zepbound during year one. Insurance or coupons can erase-or even reverse-that gap, which is why the next section focuses on coverage.

How insurance coverage flips the cost order

Employer plans vary widely. Some exclude weight-loss indications altogether, covering Ozempic only for diabetes and denying Wegovy and Zepbound. Others cover all three but require prior authorization and step therapy. Your summary of benefits or pharmacy help line can confirm which scenario applies.

Drug-specific coverage quirks:

• Ozempic only for diabetes: If you do not have type 2 diabetes, many payers will not cover Ozempic at all, making its lower cash price irrelevant.
• Wegovy coverage with higher copay: Because Wegovy is weight-loss-only, some plans place it in a higher specialty tier, pushing the copay above the $225 Wegovy card limit.
• Zepbound in middle tiers: Early 2026 plan data show Zepbound often lands in Tier 3 or 4 with a fixed $90-$125 copay, which the $150 coupon can zero out. See our coverage deep dives for specific insurers (Aetna, Anthem, TRICARE).

Use your plan’s formulary search tool before you and your doctor settle on a brand.

Other strategies if all three brands are cash-pay

If you must pay list price, consider these approaches:

Split larger pens when FDA labeling allows: The Ozempic 2 mg pen can deliver eight 0.25 mg or 0.5 mg doses, effectively halving the per-dose cost during titration. Always follow your pharmacist’s guidance and the FDA-approved pen dial settings.

Ask your doctor about a temporary starter dose pause: Clinical guidelines permit longer holds between titration steps if side effects are severe (Yao et al., 2024). A two-week pause cuts two injections from the pack and stretches your refill cycle-but clear it with your prescriber first.

File a manufacturer patient assistance application: Novo Nordisk and Eli Lilly both run need-based programs that can provide medication at no cost for 12 months if your household income is below 400% of the federal poverty level (PPARx).

Compare cash prices at local pharmacies on Rx.com with a free discount card. While discounts on these brands are usually small, the lookup is free and gives you the absolute lowest retail option available in your zip code.

Are compounded GLP-1 molecules cheaper?

Compounded semaglutide from $99 per month and compounded tirzepatide from $149 per month are available through the Rx.com weight loss program on a 12-month plan. A licensed provider reviews your health intake, and a 503A pharmacy prepares the prescription. These compounded versions are not FDA-approved and are not the same as any brand-name medication. They may be an option if you cannot obtain insurance coverage for the branded drugs and your clinician determines you are an appropriate candidate.

Because they are created for an individual patient, compounded prescriptions are not interchangeable with brand pens; you and your prescriber must decide together whether the potential cost savings outweigh the regulatory and safety considerations outlined in our compounded semaglutide safety guide and compounded tirzepatide potency guide.